Zacks Research Comments on AstraZeneca PLC’s Q3 2025 Earnings (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) – Equities researchers at Zacks Research lifted their Q3 2025 earnings estimates for AstraZeneca in a research report issued to clients and investors on Wednesday, August 28th. Zacks Research analyst R. Department now forecasts that the company will earn $1.17 per share for the quarter, up from their previous forecast of $1.15. The consensus estimate for AstraZeneca’s current full-year earnings is $4.06 per share.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business earned $1.08 EPS.

AZN has been the topic of a number of other reports. TD Cowen boosted their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised their target price on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. The Goldman Sachs Group initiated coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Finally, Barclays raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

AZN stock opened at $87.62 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market cap of $271.67 billion, a PE ratio of 42.95, a P/E/G ratio of 1.63 and a beta of 0.45. The business has a 50 day moving average of $80.81 and a 200-day moving average of $74.91. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68.

AstraZeneca Cuts Dividend

The company also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be given a dividend of $0.49 per share. The ex-dividend date is Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s payout ratio is 48.04%.

Hedge Funds Weigh In On AstraZeneca

Large investors have recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new position in AstraZeneca in the 2nd quarter worth $362,000. Clearbridge Investments LLC grew its stake in shares of AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after buying an additional 186,010 shares during the last quarter. Dana Investment Advisors Inc. purchased a new position in shares of AstraZeneca in the second quarter worth about $204,000. Granite Bay Wealth Management LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at about $332,000. Finally, Truist Financial Corp boosted its holdings in AstraZeneca by 4.6% during the 2nd quarter. Truist Financial Corp now owns 250,478 shares of the company’s stock valued at $19,535,000 after acquiring an additional 11,074 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.